. 2022 Feb 18;36:5–9. doi: 10.1016/j.mmcr.2022.02.002

Table 1.

In vitro antifungal susceptibility test results and presence of mutation detected on CYP51A gene sequence of the nine isolates analyzed.

Isolate	Days after first hospitalization	Clinical specimen	CLSI MIC (μg/mL)						CYP51A mutation
Isolate	Days after first hospitalization	Clinical specimen	MCFG	CPFG	AMPH-B	ITC	VRC	POS	CYP51A mutation
LIF 3297	+12	Renal abscess	0.03	0.25	1	0.5	2	0.25	None
LIF 3309	+43	Renal abscess	0.015	0.12	2	0.5	2	0.25	None
LIF 3365	+114	Renal abscess	0.015	0.5	2	0.5	4	0.5	None
LIF 3492	+426	Prostate	0.015	0.25	2	0.5	2	0.25	None
LIF 3519	+427	Prostate	0.015	0.12	2	0.5	1	0.25	None
LIF 3495	+456	Prostate	0.015	0.25	1	0.5	1	0.25	None
LIF 3545	+489	Prostate	0.015	0.12	1	1	4	0.25	None
LIF 3546	+489	Renal capsule	0.015	0.12	2	2	>8	0.5	G448S
LIF 3608	+740	Pleural fluid	0.015	0.25	2	2	>8	1	G448S

MICs were determined using CLSI method M38-A2. MCFG, micafungin; CPFG, caspofungin; AMPH-B, amphotericin B; ITC, itraconazole; VRC, voriconazole; POS, posaconazole.